

Special Issue

Diagnosis, Pathogenesis and Treatment of Pancreatic Ductal Adenocarcinoma

Message from the Guest Editors

Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer, originating from the epithelial cells of the main pancreatic duct. The pathogenesis of PDAC is not fully understood, but includes various risk factors such as genetic predisposition, chronic pancreatitis, smoking, obesity, and diabetes. Genetic mutations play a significant role in the development of PDAC, with KRAS, TP53, and CDKN2A among the most commonly altered genes. Treatment for PDAC depends on the stage of the cancer and the patient's overall health status. Early stage disease may be treated with surgical resection, while later stages or metastatic PDAC might require chemotherapy, radiation therapy, or targeted therapy. Novel treatment approaches, such as immunotherapy and personalized medicine, are being explored in order to improve patient outcomes. This Special Issue aims to provide an overview of the advancements in preclinical and clinical practices in the field of the treatment of PDAC. We invite authors to submit original research and review articles focusing on this important topic.

Guest Editors

Dr. Teresa Perra

Department of Medicine, Surgery and Pharmacy, Unit of General Surgery, University of Sassari, 07100 Sassari, Italy

Prof. Alberto Porcu

Department of Medicine, Surgery and Pharmacy, Unit of General Surgery, University of Sassari, 07100 Sassari, Italy

Deadline for manuscript submissions

closed (30 April 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/200638

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).